Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

UPDATE 1-'Really good news': UK health minister welcomes Oxford/AstraZeneca vaccine results

Published 2020-11-23, 03:07 a/m
© Reuters.

(Adds more quotes)

LONDON, Nov 23 (Reuters) - British Health Secretary Matt Hancock said it was "fantastic news" that data on Monday showed that a COVID-19 vaccine developed by AstraZeneca with Oxford University could be up to 90% effective and reduce its transmission.

"These figures ... show that the vaccine in the right dosage can be up to 90% effective," he told Sky News, after an announcement from AstraZeneca. got 100 million doses on order and should all that go well, the bulk of the rollout will be in the new year."

Hancock said AstraZeneca, Oxford and the medicine regulator would have to study the results to see how best to administer the vaccine once it was found to be safe.

"One of the things that regulator will need to look at is whether the programme for how the doses are done which can lead to the 90% effectiveness figure, whether that is the appropriate way to take the Oxford vaccine forward," he told BBC TV.

He also said there was evidence in the report that the vaccine could reduce transmission of the disease.

"Now of course that would be very good news if confirmed, because obviously what we want to do is not only stop people from getting the disease but also stop its transmission," he said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.